Analyst firms · Leerink Partners · FDMT
Leerink Partners FDMT price target and rating history
4D Molecular Therapeutics Inc. (FDMT) · Health Care
Leerink Partners rates 4D Molecular Therapeutics Inc. (FDMT) Outperform with a $24 price target, as of its latest action on Oct 18, 2023. It has published 3 rating actions on FDMT since January 2022, including 1 upgrade and 1 downgrade. Across 3 firms with a FDMT price target in the last 12 months, the median target is $33.
- Current rating
- Outperform
- Price target
- $24
- Median target, all firms
- $33
- Actions on FDMT
- 3
Leerink Partners price target on FDMT
Every Leerink Partners rating on FDMT
- Oct 18, 2023
- Aug 12, 2022
- Jan 4, 2022
How other firms rate FDMT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | $20 | Sep 14, 2026 |
| B. Riley Securities | Buy | $37 | Jul 31, 2026 |
| Barclays | Overweight | $33 | Jan 28, 2026 |
Questions about Leerink Partners and FDMT
- What is Leerink Partners's price target for FDMT?
- Leerink Partners's latest stated price target for 4D Molecular Therapeutics Inc. (FDMT) is $24, from its action on Oct 18, 2023.
- What is Leerink Partners's rating on FDMT?
- Leerink Partners rates FDMT Outperform, a bullish rating, as of Oct 18, 2023.
- When did Leerink Partners last change its view on FDMT?
- On Oct 18, 2023, Leerink Partners upgrades to Outperform from Market Perform, price target $24.
- How does Leerink Partners's FDMT target compare with other analysts?
- Across 3 firms with a FDMT price target in the last 12 months, the median target is $33.
More FDMT rating histories
All Leerink Partners ratingsFDMT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.